Fiscal year 2024 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses TERN in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named TERN in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Amy Burroughs | $563,701 | $0 | $807,750 | $6,476,968 | $375,000 | $0 | $17,083 | $8,240,502 |
| Chief Executive Officer and Director | ||||||||
| Mark Vignola | 475,000 | 810,417 | 375,375 | 528,120 | 190,000 | 0 | 538,025 | 2,916,937 |
| Former Chief Financial Officer and Treasurer | ||||||||
| Melita Sun Jung | 319,051 | 20,000 | 0 | 1,687,198 | 166,002 | 0 | 3,833 | 2,196,084 |
| Chief Business Officer | ||||||||
| Erin Quirk | 232,544 | 473,529 | 409,500 | 576,131 | 0 | 0 | 243,259 | 1,934,963 |
| Former President, Head of Research & Development | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2024 total | FY2023 total | FY2022 total | Δ FY2023→2024 |
|---|---|---|---|---|
| Amy Burroughs | $8,240,502 | — | — | — |
| Mark Vignola | 2,916,937 | 3,137,032 | — | −220,095 |
| Melita Sun Jung | 2,196,084 | — | — | — |
| Erin Quirk | 1,934,963 | 4,665,845 | — | −2,730,882 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
No insider equity transactions reported since the proxy statement.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Mark Vignola | OTHER | — | — | — | — | — | $375,375 |
| Erin Quirk | OTHER | — | — | — | — | — | 409,500 |
| Amy Burroughs | OTHER | — | — | — | — | — | 807,750 |
Grant-level vehicle detail not disclosed.
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Mark Vignola | Option | 137,500 | 5.46 | — |
| Melita Sun Jung | RSU | 539,758 | — | 5,301,406 |
| Melita Sun Jung | Option | 6,728,887 | 8.33 | — |
| Melita Sun Jung | Option | 3,881,500 | 7.61 | — |
| Melita Sun Jung | RSU | 157,672 | — | 2,685,001 |
| Amy Burroughs | PSU | 150,000 | — | 831,000 |
| Mark Vignola | Option | 187,500 | 8.94 | — |
| Mark Vignola | Option | 150,812 | 9.24 | — |
| Mark Vignola | Option | 22,500 | 10.72 | — |
| Mark Vignola | Option | 17,605 | 5.36 | — |
| Melita Sun Jung | Option | 475,000 | 5.08 | — |
| Amy Burroughs | Option | 1,250,000 | 7.31 | — |
| Melita Sun Jung | Option | 10,610,387 | 8.07 | — |
| Mark Vignola | Option | 76,995 | 6.86 | — |
| Mark Vignola | PSU | 68,750 | — | 380,875 |
Terns Pharmaceuticals uses a performance-based compensation program consisting of base salary, annual cash bonuses tied to achievement of corporate goals, and equity awards (stock options and RSUs) to attract, retain, and align executive interests with stockholder interests. The company is an emerging growth company and has elected scaled disclosure requirements, so a full CD&A is not required or provided.
| CEO STI target (% of salary) | 50% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Alpine Rewards |
| Clawback policy | True |
| Anti-hedging | False |
| Anti-pledging | False |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Jill QuigleyIndependent · Audit (Chair) · Nominating/Governance | $51,229 | $0 | $147,585 | $0 | $101,643 | $300,457 |
| Heather TurnerIndependent · Audit · Newly elected | 5,679 | 0 | 244,121 | 0 | — | 249,800 |
| David FellowsIndependent · Board Chair · Compensation · Nominating/Governance (Chair) | 51,049 | 0 | 183,780 | 0 | — | 234,829 |
| Radhika TripuraneniIndependent · Audit · Research and Development (Chair) | 37,654 | 0 | 168,268 | 0 | — | 205,922 |
| Ann TaylorIndependent · Departed during FY | 32,694 | 0 | 168,268 | 0 | — | 200,962 |
| Jeffrey KindlerIndependent · Compensation (Chair) | 30,000 | 0 | 168,268 | 0 | — | 198,268 |
| Hongbo LuIndependent · Nominating/Governance · Research and Development | 29,698 | 0 | 168,268 | 0 | — | 197,966 |
| Carl GordonIndependent · Departed during FY | 24,000 | 0 | 168,268 | 0 | — | 192,268 |
| Robert AzelbyIndependent · Compensation · Newly elected | 0 | 0 | 0 | 0 | 0 | 0 |
| Amy BurroughsEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 10,000 / 8,000 |
| Stock ownership guideline | — |
| Component | FY2024 |
|---|---|
| Cash retainers and fees | $262,003 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $101,643 |
| Total cost of the board | $363,646 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Terns Pharmaceuticals, Inc. | 2024 | Amy Burroughs | $563,701 | $807,750 | $6,476,968 | $375,000 | $8,240,502 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Amy Burroughs | DEF 14A | 2025-04-29 | 0000950170-25-060138 | Section “2024 Summary Compensation Table”. As printed: 8,240,502. Filing ↗machine: t5 · r3 · c26 · span 385759–385768 |
| 2 | Section 01, Mark Vignola | DEF 14A | 2025-04-29 | 0000950170-25-060138 | Section “2024 Summary Compensation Table”. As printed: 2,916,937. Filing ↗machine: r6 · c29 · span 416551–416560 |
| 3 | Section 01, Melita Sun Jung | DEF 14A | 2025-04-29 | 0000950170-25-060138 | Section “2024 Summary Compensation Table”. As printed: 2,196,084. Filing ↗machine: t5 · r8 · c27 · span 437336–437345 |
| 4 | Section 01, Erin Quirk | DEF 14A | 2025-04-29 | 0000950170-25-060138 | Section “2024 Summary Compensation Table”. As printed: 1,934,963. Filing ↗machine: r4 · c29 · span 396035–396044 |
| 5 | Section 03, Mark Vignola OTHER | DEF 14A | 2025-04-29 | 0000950170-25-060138 | Section “EXECUTIVE COMPENSATION &” · grants of plan-based awards table. Filing ↗machine: t5 · r6 · c12 · span 411439–411446 |
| 6 | Section 03, Erin Quirk OTHER | DEF 14A | 2025-04-29 | 0000950170-25-060138 | Section “EXECUTIVE COMPENSATION &” · grants of plan-based awards table. Filing ↗machine: t5 · r4 · c12 · span 390796–390803 |
| 7 | Section 03, Amy Burroughs OTHER | DEF 14A | 2025-04-29 | 0000950170-25-060138 | Section “EXECUTIVE COMPENSATION &” · grants of plan-based awards table. Filing ↗machine: t5 · r3 · c12 · span 380457–380464 |
| 8 | Section 08, Jill Quigley | DEF 14A | 2025-04-29 | 0000950170-25-060138 | Section “Director Compensation”. As printed: 300,457. Filing ↗machine: t10 · r6 · c14 · span 712796–712803 |
| 9 | Section 08, Heather Turner | DEF 14A | 2025-04-29 | 0000950170-25-060138 | Section “Director Compensation”. As printed: 249,800. Filing ↗machine: t10 · r9 · c15 · span 730300–730307 |
| 10 | Section 08, David Fellows | DEF 14A | 2025-04-29 | 0000950170-25-060138 | Section “Director Compensation”. As printed: 234,829. Filing ↗machine: t10 · r2 · c15 · span 689449–689456 |
| 11 | Section 08, Radhika Tripuraneni | DEF 14A | 2025-04-29 | 0000950170-25-060138 | Section “Director Compensation”. As printed: 205,922. Filing ↗machine: t10 · r8 · c15 · span 724531–724538 |
| 12 | Section 08, Ann Taylor | DEF 14A | 2025-04-29 | 0000950170-25-060138 | Section “Director Compensation”. As printed: 200,962. Filing ↗machine: t10 · r7 · c15 · span 718735–718742 |
| 13 | Section 08, Jeffrey Kindler | DEF 14A | 2025-04-29 | 0000950170-25-060138 | Section “Director Compensation”. As printed: 198,268. Filing ↗machine: t10 · r4 · c15 · span 701182–701189 |
| 14 | Section 08, Hongbo Lu | DEF 14A | 2025-04-29 | 0000950170-25-060138 | Section “Director Compensation”. As printed: 197,966. Filing ↗machine: t10 · r5 · c15 · span 706961–706968 |
| 15 | Section 08, Carl Gordon | DEF 14A | 2025-04-29 | 0000950170-25-060138 | Section “Director Compensation”. As printed: 192,268. Filing ↗machine: t10 · r3 · c15 · span 695398–695405 |
| 16 | Section 08, Robert Azelby | DEF 14A | 2025-04-29 | 0000950170-25-060138 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 17 | Section 08, Amy Burroughs | DEF 14A | 2025-04-29 | 0000950170-25-060138 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 18 | Section 01 trend, Δ column (computed) | Computed | — | computed | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 19 | Section 09b board cost (computed) | Computed | — | computed | Cash 262,003 + equity 0 + all other 101,643 = 363,646, summed across the director compensation table rows.machine: formula: Σ = 363,646 |
| 20 | Terns Pharmaceuticals, Inc. (subject), Section 10b CEO total | DEF 14A | 2025-04-29 | 0000950170-25-060138 | CEO total compensation as printed in Terns Pharmaceuticals, Inc.'s own proxy. As printed: 8,240,502. Filing ↗machine: t5 · r3 · c26 · span 385759–385768 |